

AMENDMENTS TO THE CLAIMS:

This listing of claims will replace all prior versions, and listings, of claims in the application.

LISTING OF CLAIMS:

Claims 1 to 48 (Canceled)

49. (Currently amended) A vaccine comprising a recombinant attenuated respiratory syncytial virus, the genome of which contains the reverse complement of an mRNA coding sequence operatively linked to a polymerase binding site of a respiratory syncytial virus, and a pharmaceutically acceptable carrier, wherein the genome comprises a genetic alteration wherein the genetic alteration is a deletion ~~[[of]]~~ within the NS1 gene.

Claims 50 to 52 (Canceled)

53. (Previously presented) The vaccine of claim 49, wherein the virus is capable of going through only one round of replication in the host.

Claims 54 to 56 (Canceled)

57. (Currently amended) An immunogenic composition comprising a recombinant attenuated respiratory syncytial virus, the genome of which contains the reverse complement of an mRNA coding sequence operatively linked to a polymerase binding site of a respiratory syncytial virus, and a pharmaceutically acceptable carrier, wherein the genome comprises a genetic alteration wherein the genetic alteration is a deletion ~~[[of]]~~ within the NS1 gene.

Claims 58 to 68 (Canceled)

69. (Previously presented) The immunogenic composition of claim 57, wherein the virus is capable of going through only one round of replication in the host.

70. (Previously presented) A vaccine comprising the immunogenic composition of claim 57.

Claims 71 and 72 (Canceled)

73. (Currently amended) A pharmaceutical composition comprising (1) a recombinant attenuated respiratory syncytial virus, the genome of which contains the reverse complement of an mRNA coding sequence operatively linked to a polymerase binding site of a respiratory syncytial virus, and a pharmaceutically acceptable carrier, wherein the genome comprises a genetic alteration wherein the genetic alteration is a deletion [[of]] within the NS1 gene; and (2) a pharmaceutically acceptable carrier.

Claims 74 to 82 (Canceled)

83. (Previously presented) The pharmaceutical composition of claim 73, wherein the virus is capable of going through only one round of replication in the host.